LIFE实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States...

Stats
今日成交量	250 293
平均成交量	577 632
市值	109.08M
EPS	$0 ( 2024-03-14 )
下一个收益日期	( $-0.240 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.710
ATR14	$0.00400 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-05	Shukla Sanjay	Buy	10 375	Common stock
2024-02-05	Shukla Sanjay	Sell	10 375	Restricted Stock Unit
2024-02-05	Broadfoot Jill Marie	Buy	3 750	Common stock
2024-02-06	Broadfoot Jill Marie	Sell	1 590	Common stock
2024-02-05	Broadfoot Jill Marie	Sell	3 750	Restricted Stock Unit

INSIDER POWER
92.94
Last 99 transactions
Buy: 4 079 228 \| Sell: 350 127

音量相关性

長: 0.01 (neutral)

短: -0.72 (moderate negative)

Signal:(42.713) Neutral

aTyr Pharma Inc 相关性

10 最正相关
FXCO	0.899
NNBR	0.869
BNIXU	0.857
CHKP	0.856
EWTX	0.853
KURA	0.848
FGEN	0.848
SWTX	0.841
IDYA	0.839
FATE	0.836

10 最负相关
RMRM	-0.933
RTPY	-0.85
HOLUU	-0.834
TYHT	-0.821
FTOCU	-0.821
BFRI	-0.816
RAAC	-0.811
WINT	-0.81
EMBCV	-0.809
DISH	-0.804

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

aTyr Pharma Inc 相关性 - 货币/商品

0.23
( neutral )

-0.20
( neutral )

0.00
( neutral )

-0.34
( neutral )

aTyr Pharma Inc 财务报表

Annual	2023
营收:	$353 000
毛利润:	$-2.39M (-676.49 %)
EPS:	$-0.940

FY	2023
营收:	$353 000
毛利润:	$-2.39M (-676.49 %)
EPS:	$-0.940

FY	2022
营收:	$10.39M
毛利润:	$8.69M (83.68 %)
EPS:	$-1.560

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.770

Financial Reports:

No articles found.

aTyr Pharma Inc

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.